| Kidney injury biomarkers in an academic hospital setting: where are we now? TT van Duijl, LR Ruhaak, JW de Fijter, CM Cobbaert The Clinical biochemist Reviews 40 (2), 79, 2019 | 33 | 2019 |
| Structure–Affinity Relationships and Structure–Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists L Xia, WAC Burger, JPD van Veldhoven, BJ Kuiper, TT van Duijl, ... Journal of Medicinal Chemistry 60 (17), 7555-7568, 2017 | 33 | 2017 |
| Equilibrium and kinetic selectivity profiling on the human adenosine receptors D Guo, GS Dijksteel, T van Duijl, M Heezen, LH Heitman, AP IJzerman Biochemical Pharmacology 105, 34-41, 2016 | 27 | 2016 |
| Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury TT Van Duijl, D Soonawala, JW De Fijter, LR Ruhaak, CM Cobbaert Clinical Proteomics 18 (1), 10, 2021 | 21 | 2021 |
| Development and provisional validation of a multiplex LC-MRM-MS test for timely kidney injury detection in urine TT van Duijl, LR Ruhaak, NPM Smit, MM Pieterse, FP Romijn, N Dolezal, ... Journal of Proteome Research 20 (12), 5304-5314, 2021 | 21 | 2021 |
| A binding kinetics study of human adenosine A3 receptor agonists L Xia, A Kyrizaki, DK Tosh, TT van Duijl, JC Roorda, KA Jacobson, ... Biochemical pharmacology 153, 248-259, 2018 | 17 | 2018 |
| Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer JM Janssen, RB Verheijen, TT van Duijl, L Lin, MM van den Heuvel, ... Clinical and Translational Science 15 (8), 1916-1925, 2022 | 14 | 2022 |
| Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors RB Verheijen, TT Van Duijl, MM Van den Heuvel, D Vessies, M Muller, ... Cancer Chemotherapy and Pharmacology 87, 269-276, 2021 | 8 | 2021 |
| Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry TT van Duijl, LR Ruhaak, EK Hoogeveen, R de Mutsert, FR Rosendaal, ... Annals of Clinical Biochemistry 59 (6), 420-432, 2022 | 6 | 2022 |
| Multiplex LC-MS/MS testing for early detection of kidney injury: a next-generation alternative to conventional immunoassays? TT van Duijl, LR Ruhaak, C van Kooten, JW de Fijter, CM Cobbaert The Journal of Applied Laboratory Medicine 7 (4), 923-930, 2022 | 3 | 2022 |
| Variant mapping using mass spectrometry–based proteotyping as a diagnostic tool in von Willebrand disease IC Kreft, TT van Duijl, C van Kwawegen, F Atiq, W Phan, MBP Schuller, ... Journal of Thrombosis and Haemostasis 22 (7), 1894-1908, 2024 | 2 | 2024 |
| Urinary kidney injury biomarkers are associated with ischemia-reperfusion injury severity in kidney allograft recipients TT van Duijl, ENM de Rooij, MM Treep, ME Koelemaij, FP Romijn, ... Clinical Chemistry 69 (8), 924-935, 2023 | 2 | 2023 |
| OC 15.3 Multiplex Quantitation of Coagulation and Fibrinolysis Markers: An Upcoming Approach to Unravel Bleeding and Thrombotic Disorders T van Duijl, E Smit, M Boon-Spijker, C van der Zwaan, J Meijers, ... Research and Practice in Thrombosis and Haemostasis 7, 2023 | 1 | 2023 |
| Verbetering van de diagnostiek en behandeling van personen met een onverklaarde bloedingsneiging in Nederland ALL Monard, CMA Mussert, YMC Henskens, M Kruip, REG Schutgens, ... | 1 | 2023 |
| Bleeding Disorder of Unknown Cause (BDUC): an illustrated review on current practice, knowledge gaps and future perspectives. ALL Monard, CMA Mussert, TT van Duijl, MJHA Kruip, YMC Henskens, ... Research and Practice in Thrombosis and Haemostasis, 102625, 2024 | | 2024 |
| Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel FGG mutation A Monard, E Castoldi, I De Simone, K Wichapong, T van Duijl, ... Frontiers in Cardiovascular Medicine 11, 1488602, 2024 | | 2024 |
| Proteomic screening in bleeding disorders of unknown cause TT van Duijl, AL Monard, CM Mussert, YM Henskens, RE Schutgens, ... HAEMOPHILIA 30, 158-159, 2024 | | 2024 |
| Characterization and Quantification of Von Willebrand Factor Proteoforms in Von Willebrand Disease Patients and Healthy Controls: Insights from the Win-Study I charlotte Kreft, TT van Duijl, C Van Kwawegen, W Phan, M Schuller, ... Blood 142, 2606, 2023 | | 2023 |
| PB0819 Quantification of von Willebrand Factor Proteoforms by Mass Spectrometry-Based Proteomics Reveals Differential Variant-to-Wild Type Stoichiometry in Subtypes of von … T van Duijl, I Kreft, C van Kwawegen, F Atiq, W Phan, M Schuller, ... Research and Practice in Thrombosis and Haemostasis 7, 2023 | | 2023 |
| Quantitative protein mass spectrometry for kidney injury biomarker translation towards the clinical laboratory TT van Duijl Leiden University, 2023 | | 2023 |
